Endovascular procedures may play a role in renal artery stenosis (RAS) treatment in attempt to preserve renal function and improve hypertension control. We determined renal outcome and the incidence of restenosis in patients with RAS treated with renal percutaneous transluminal angioplasty and stenting (RPTAs) and medical therapy versus patients with RAS treated only with medical therapy. We performed an observational study based on 93 patients with RAS. In all, 53 patients underwent RPTAs in association with medical therapy and 40 patients were only treated pharmacologically. In patients receiving RPTAs, a better renal outcome, a decrease of restenosis rate, and systolic—diastolic blood pressure were associated with angiotensin receptor blockers (ARBs) + angiotensin-converting enzyme inhibitors (ACE-is) therapy. In patients treated with medical therapy alone, renal improvement was related to ARBs in association with BBs (β-blockers; P < .0001). This study suggests that medical therapy may exert beneficial effects in patients with RAS.
Cooper CJ, Murphy TP, Matsumoto A., et al. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J. 2006; 152(1):59-66.
2.
Van de Ven PJ , Kaatee R., Beutler JJ, et al. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised trail. Lancet. 1999;353(9149):282-286.
3.
Dorros G., Prince C., Mathiak L.Stenting of renal artery stenosis achieves better relief of the obstructive lesion than balloon angioplasty. Catheter Cardiovasc Diagn . 1993;29(3):191-198.
4.
Gao YS, Nagao T., Bond RA, Janssens WJ, Vanhoutte PMNebivolol induces endothelium-dependent relaxations of canine arteries. J Cardiovasc Pharmacol. 1991;17(6):964-969.
5.
Coen G., Manni M., Giannoni MF, et al. Ischemic nephropathy in an elderly nephrologic and hypertensive population. Am J Nephrol. 1998;18(3):221-227.
6.
Preston RA, Epstein M.Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. J Hypertens. 1997;15(12 pt 1):1365-1377.
7.
Epstein FHOxygen and renal metabolism. Kidney Int. 1997 ; 51(2):381-385.
8.
Pohl MARenovascular hypertension and ischemic nephropathy. In: Wilcox CS, Schrier RW , eds. Atlas of Diseases of the Kidney. 1st ed. Philadelphia, PA: Current Medicine ; 1999:3.1-3.21.
9.
Meyrier A., Hill GS, Simon P.Ischemic renal diseases: new insights into old entities. Kidney Int. 1998;54(1):2-13.
10.
Truong LD, Farhood A., Tasby J., Gillum D.Experimental chronic renal ischemia: morphologic and immunologic studies. Kidney Int. 1992;41(6):1676-1689.
11.
Textor SC, Tarazi RC, Novick AC, Bravo EL, Fouad FMRegulation of renal hemodynamics and glomerular filtration rate in patients with renovascular hypertension during converting enzyme inhibition with captopril . Am J Med. 1984;76(5B): 29-37.
12.
Tokuyama H., Hayashi K., Matsuda H., et al. Differential regulation of elevated renal angiotensin II in chronic renal ischemia. Hypertension. 2002 ;40(1):34-40.
13.
Epstein M.Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006;119(11): 912-919.
14.
Zeller T., Rastan A., Rothenpieler U., Muller C.Restenosis after stenting of atherosclerotic renal artery stenosis: is there a rationale for the use of drug-eluting stents? Catheter Cardiovasc Interv. 2006;68(1):125-130.
15.
Cianci R., Gigante A., Polidori L., et al. In-stent restenosis of the renal artery in a single kidney patient: the role of ACEI in the therapeutic choice. Angiology.2009;60(4):496-503.
16.
Textor SCAtherosclerotic renal artery stenosis: overtreated but underrated? J Am Soc Nephrol. 2008;19(4):656-659.
17.
Kloner RA, Textor SC, Tavel MERenovascular hypertension: problems in evaluation and management. Chest. 2002;121(3): 964-968.
18.
Textor SC, McKusick MM, Misra S., Glockner J.Timing and selection for renal revascularization in an era of negative trials: what to do?Prog Cardiovasc Dis. 2009;52(3):220-228.
19.
Webster J., Marshall F., Abdalla M., et al. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis . J Hum Hypertens. 1998;12(5):329-335.
20.
van Jaarsveld BC, Krijnen P., Pieterman H., et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med. 2000;342(14):1007-1014.
21.
Plouin PF, Chatellier G., Darné B., Raynaud A.Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Hypertension. 1998;31(3):822-829.
22.
Coen G., Moscaritolo E., Catalano C., et al. Atherosclerotic renal artery stenosis: one year outcome of total and separate kidney function following stenting. BMC Nephrol . 2004;5(1):15.
23.
O’Keefe JH Jr, Cordain L., Harris WH, Moe RM, Vogel R.Optimal low-density lipoprotein is 50 to 70 mg/dL: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43(11): 2142-2146.
24.
De Lorenzo F., Feher M., Martin J., Collot-Teixeira S., Dotsenko O., McGregor JLStatin therapy-evidence beyond lipid lowering contributing to plaque stability. Curr Med Chem. 2006;13(28): 3385-3393.
25.
Shepherd J. , Kastelein JJ, Bittner V., et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol . 2007;2(6):1131-1139.
26.
Alnaeb ME, Youssef F., Mikhailidis DP, Hamilton G.Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease . Angiology. 2006;57(1):65-71.
27.
Paraskevas KI, Hamilton G., Cross JM, Mikhailidis DPAtherosclerotic renal artery stenosis: association with emerging vascular risk factors. Nephron Clin Pract. 2008;108(1):c56-c66.
28.
Stivali G., Cerroni F., Bianco P., Fiaschetti P., Cianci R.Images in cardiovascular medicine. Carotid plaque reduction after medical treatment. Circulation. 2005;112(17):e276-e277.
29.
Duranay M., Kanbay M., Akay H., et al. Nebivolol improves renal function in patients who underwent angioplasty due to renal artery stenosis: a pilot study. Nephron Clin Pract. 2010;114(3): c213-c217.
30.
Paraskevas KI, Giannoukas AD, Mikhailidis DPRenal function impairment in peripheral arterial disease: an important parameter that should not be neglected. Ann Vasc Surg.2009;23(5):690-699.
